Skip to main content

Table 2 Laboratory and electrophysiological features, therapy, and outcome of patients with GBS

From: Clinical features and outcome of Guillain–Barre syndrome in Saudi Arabia: a multicenter, retrospective study

Variable

N (%) or median (IQR)

CSF a

123 (78.8)

 Protein level, g/L

0.63 (0.39–1.13)

 Protein > 0.45 g/L

85 (69.1)

 Cell count/µl

1.0 (0–3)

 Cell count > 5/µl

13 (10.6)

 Cytoalbuminological dissociation

85 (69.1)

Low FVC (< 1.5L or 20 mL/kg) at admission

23/84 (27.4)

MRI spine: root enhancement

32/75 (42.7)

MRI brain: cranial nerve enhancement

2/76 (2.6)

Electrophysiological subtypes as reportedb

146 (93.6)

AIDP

55/146 (37.7)

AMAN

43/146 (29.5)

AMSAN

28/146 (19.2)

Equivocal

9/146 (6.2)

Normal

11/146 (7.5)

Received GBS Therapyc

151 (96.8)

 IVIg

133/151 (88.1)

 PLEX

18/151 (11.9)

Repeated therapy d

38/151 (25.2)

 IVIg–PLEX

19/38 (50.0)

 IVIg–IVIg

11/38 (28.9)

 PLEX–IVIg

7/38 (18.4)

 PLEX–PLEX

1/38 (2.6)

Duration of hospitalization (N = 145, 93%)

2.4 (1–8) weeks

Outcome at follow-up

97 (62.2%)

Able to walk independently at < 6 months

37/97 (38.1)

Able to walk independently at 6 – 9 months

11/97 (11.3)

Able to walk independently at > 9 months

32/97 (33.0)

Able to walk with support at > 9 months

10/97 (10.3)

Unable to walk at > 9 months

7/97 (7.2)

Died (Septicemia)

1/156 (0.64)

  1. AIDP acute inflammatory demyelinating polyradiculoneuropathy, AMAN acute motor axonal neuropathy, AMSAN acute motor-sensory axonal neuropathy, IVIg intravenous immunoglobulin, MFS Miller-Fisher syndrome, N number of patients for whom data are available, PLEX plasma exchange
  2. aMedian time after the onset of symptoms = 5 (2–14) days, and maximum CSF cell count = 23 cells/µl
  3. bMedian time after the onset of symptoms = 10 (5–20) days
  4. cMedian time after the onset of symptoms = 7 (4–13.75) days
  5. dMedian time after first therapy = 17 (8.5–28.5) days